이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NeoPharm 미래 성장

Future 기준 확인 2/6

NeoPharm (는) 각각 연간 18.3% 및 17.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 16% 로 예상됩니다.

주요 정보

18.3%

수익 성장률

16.9%

EPS 성장률

Personal Products 수익 성장	34.1%
매출 성장률	17.4%
향후 자기자본 수익률	16.0%
애널리스트 커버리지	Low
마지막 업데이트	22 Apr 2024

최근 미래 성장 업데이트

Recent updates

NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Jun 13

How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

Mar 02

We're Watching These Trends At NeoPharm (KOSDAQ:092730)

Feb 18

We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

Feb 08

NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

Jan 26

An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Jan 15

Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

Jan 04

NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Dec 24

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Dec 15

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Dec 04

Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

Nov 23

수익 및 매출 성장 예측

KOSDAQ:A092730 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (KRW Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	165,000	35,600	35,700	35,700	1
12/31/2025	145,000	30,100	29,700	29,700	1
12/31/2024	120,000	23,000	23,000	23,000	1
3/31/2024	101,735	22,516	-1,808	20,105	N/A
12/31/2023	97,105	23,213	2,435	23,263	N/A
9/30/2023	92,271	20,733	22,967	24,024	N/A
6/30/2023	89,292	19,781	20,199	21,423	N/A
3/31/2023	86,272	18,912	18,966	19,685	N/A
12/31/2022	85,033	17,027	17,354	18,161	N/A
9/30/2022	86,805	18,245	17,373	18,071	N/A
6/30/2022	87,424	17,370	17,809	18,258	N/A
3/31/2022	87,321	16,905	18,775	19,267	N/A
12/31/2021	87,931	17,713	21,203	21,681	N/A
9/30/2021	86,802	18,207	20,320	20,881	N/A
6/30/2021	85,275	18,059	21,190	21,766	N/A
3/31/2021	85,287	18,474	18,837	19,464	N/A
12/31/2020	81,625	18,131	16,343	17,074	N/A
9/30/2020	81,413	18,734	11,309	17,364	N/A
6/30/2020	82,618	19,935	12,028	18,544	N/A
3/31/2020	82,680	19,901	16,909	24,255	N/A
12/31/2019	83,240	19,245	12,030	19,224	N/A
9/30/2019	79,611	18,002	15,245	17,190	N/A
6/30/2019	74,863	16,675	13,488	15,234	N/A
3/31/2019	69,500	15,795	10,168	12,149	N/A
12/31/2018	66,275	15,370	14,096	16,179	N/A
9/30/2018	63,143	13,682	11,351	13,893	N/A
6/30/2018	60,236	13,105	12,244	14,629	N/A
3/31/2018	57,175	12,514	11,537	12,814	N/A
12/31/2017	53,634	11,559	N/A	10,646	N/A
9/30/2017	49,765	9,814	N/A	10,212	N/A
6/30/2017	46,739	9,365	N/A	9,866	N/A
3/31/2017	43,164	8,096	N/A	9,548	N/A
12/31/2016	42,369	7,742	N/A	9,157	N/A
9/30/2016	43,097	5,955	N/A	8,664	N/A
6/30/2016	41,999	5,419	N/A	6,471	N/A
12/31/2015	35,965	3,407	N/A	6,095	N/A
9/30/2013	19,350	1,475	N/A	2,078	N/A
6/30/2013	18,517	1,140	N/A	1,172	N/A

애널리스트 미래 성장 예측

수입 대 저축률: A092730 의 연간 예상 수익 증가율( 18.3% )이 saving rate( 2.5% 보다 높습니다. ).

수익 vs 시장: A092730 의 연간 수익( 18.3% ) KR 시장( 28.8% 보다 느리게 성장할 것으로 예상됩니다. 28.8% 연간).

고성장 수익: A092730 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: A092730 의 수익(연간 17.4% ) KR 시장( 10.5% 보다 빠르게 성장할 것으로 예상됩니다. 10.5% 연간).

고성장 수익: A092730 의 수익(연간 17.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: A092730 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 16 %).

NeoPharm 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Price target increased to ₩46,333

Analysts lower EPS estimates to ₩2,091

Recent updates

NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price

NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Full year 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₩700 per share at 2.9% yield

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₩2,177 (vs ₩2,265 in FY 2021)

Now 20% undervalued

Upcoming dividend of ₩700 per share

Full year 2021 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ₩650 per share

Price target increased to ₩46,333

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS ₩2,318 (vs ₩2,570 in FY 2019)

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

We're Watching These Trends At NeoPharm (KOSDAQ:092730)

We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Investor sentiment improved over the past week

New 90-day high: ₩29,500

Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Upcoming Dividend of ₩750 Per Share

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

Analysts lower EPS estimates to ₩2,091

New 90-day low: ₩27,250

New 90-day low - ₩28,000

New 90-day low - ₩30,000

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견